Nabriva Therapeutics (NASDAQ:NBRV) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV) in a report issued on Wednesday. The firm set a “hold” rating on the biotechnology company’s stock.

Nabriva Therapeutics Price Performance

The company has a debt-to-equity ratio of 0.12, a current ratio of 0.85 and a quick ratio of 0.52. The stock has a 50 day simple moving average of $0.14 and a 200 day simple moving average of $0.61. Nabriva Therapeutics has a fifty-two week low of $1.22 and a fifty-two week high of $8.45. The company has a market cap of $45.46 million, a P/E ratio of -0.07 and a beta of 1.53.

Institutional Investors Weigh In On Nabriva Therapeutics

An institutional investor recently raised its position in Nabriva Therapeutics stock. Renaissance Technologies LLC lifted its position in Nabriva Therapeutics plc (NASDAQ:NBRV) by 102.1% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 795,938 shares of the biotechnology company’s stock after acquiring an additional 402,144 shares during the quarter. Renaissance Technologies LLC owned approximately 0.13% of Nabriva Therapeutics worth $145,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 0.27% of the company’s stock.

Nabriva Therapeutics Company Profile

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration.